Novartis Action: FDA Develops Novartis Drug for More Indications – New Data for MS Mittel Kesimpta | 09.18.24

Novartis teilte dies in de Dienstagabend mit.

The disease is seen as patients with hormonal receptor-positive, HER2-negative Brustkrebs in Stage II and III, who have a high risk of relapse. Laut Studien could Kisqali in Combination with a hormone therapy of the relapse in the story of all hormone therapies on 25 days ago. If it is useful to do something, the Krebs can no longer work.

“This trial is a more serious step forward, offering more patients with Frühstadion Brustkrebs an unemployed treatment option, while the leading study by Dennis J. Slamon is in progress.

Kisqali has the responsibility of the company relations on the treatment of fortgeschrittenem Brustkrebs-zugelassen and finds them in Europe in the Prüfung for the Zulassung in the Frühfase of the Erkrankung. If the care for the care is provided when the patient becomes ill, a treatment with such a CDK4/6-hemmer with Kisqali infringement will come.

New research into the best results of MS-Mittel Kesimpta through new data

Novartis has set the new date for the drug use, where the treatment with Multiple Sclerosis (RMS) is performed. Those data indicate that the healing is continued as first-line therapy and some of the healing of the experience is promoted.

If you have the Mittwoch Mitteilte, the data comes from the insulting Verlengerungsstudie Alithios. Annähernd 90 After the patients, who were discussed in that study with Kesimpta as First Line Therapy, they said that after a long period of time, they will learn more about the history.

If we look at the new data from another study of patients, there is intravenous anti-CD20 therapy at the highest level of disease, 12 months after that week there can be no new active treatment.

The dates were presented by Novartis at the Fachkongress ECTRIMS from 18 to 20 September in Denmark.

Basel (awp)